Immune thrombocytopenic purpura: A rare side effect in a patient treated with Imiquimod for lentigo maligna

Topical Imiquimod is increasingly used in the treatment of lentigo maligna (LM) for patients not suitable or willing for surgery. It acts as an immune response modifier and is recommended for use with caution in patients with autoimmune disorders. A review of the literature did not reveal any report...

Full description

Bibliographic Details
Main Authors: E.A. Whatling, K. Balghari, B.W.E.M. Powell
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:JPRAS Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352587817300360